Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.
2.

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.

Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M.

Neuro Oncol. 2009 Dec;11(6):747-56. doi: 10.1215/15228517-2009-012. Epub .

3.

Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer.

Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau WS, Seeger W, Grimminger F, Banat GA.

Neoplasia. 2009 Jan;11(1):48-56.

4.

Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.

Eikesdal HP, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, Kalluri R.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15040-5. doi: 10.1073/pnas.0807055105. Epub 2008 Sep 25.

5.

A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Karagiannis ED, Popel AS.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13775-80. doi: 10.1073/pnas.0803241105. Epub 2008 Sep 9.

6.

Hypoxia, angiogenesis, and lung cancer.

Goudar RK, Vlahovic G.

Curr Oncol Rep. 2008 Jul;10(4):277-82. Review.

PMID:
18778551
7.

Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.

Nyberg P, Xie L, Sugimoto H, Colorado P, Sund M, Holthaus K, Sudhakar A, Salo T, Kalluri R.

Exp Cell Res. 2008 Nov 1;314(18):3292-305. doi: 10.1016/j.yexcr.2008.08.011. Epub 2008 Aug 26.

8.

Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.

Sasaki T, Tanno S, Shibukawa K, Osanai S, Kawabe J, Ohsaki Y.

Int J Oncol. 2008 Sep;33(3):525-32.

PMID:
18695882
9.

Small cell lung cancer.

Sher T, Dy GK, Adjei AA.

Mayo Clin Proc. 2008 Mar;83(3):355-67. doi: 10.4065/83.3.355. Review.

PMID:
18316005
10.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

11.

Targeted therapies in small-cell lung cancer.

Fernainy K, Saba N.

Expert Opin Ther Targets. 2007 Aug;11(8):1033-41. Review.

PMID:
17665976
12.

Developing antiangiogenic peptide drugs for angiogenesis-related diseases.

Sulochana KN, Ge R.

Curr Pharm Des. 2007;13(20):2074-86.

PMID:
17627540
13.

Role of bevacizumab for the treatment of non-small-cell lung cancer.

Ramalingam S, Belani CP.

Future Oncol. 2007 Apr;3(2):131-9. Review.

PMID:
17381412
14.

Small cell lung cancer and targeted therapies.

Blackhall FH, Shepherd FA.

Curr Opin Oncol. 2007 Mar;19(2):103-8. Review.

PMID:
17272981
15.
16.

Angiogenesis inhibition in the treatment of lung cancer.

Vokes E, Herbst R, Sandler A.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Review.

PMID:
17143257
17.

Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.

Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ.

Lung Cancer. 2000 Sep;29(3):169-77.

PMID:
10996419
18.
19.

Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes.

Falcioni R, Cimino L, Gentileschi MP, D'Agnano I, Zupi G, Kennel SJ, Sacchi A.

Exp Cell Res. 1994 Jan;210(1):113-22.

PMID:
7505746
20.

Tumor angiogenesis: therapeutic implications.

Folkman J.

N Engl J Med. 1971 Nov 18;285(21):1182-6. Review. No abstract available.

PMID:
4938153
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk